UK MRC (UK Medical Research Council) biobank and stem cells under scrutiny:
This article was originally published in Clinica
Executive Summary
The UK Medical Research Council (MRC) is to stand before the House of Commons' Select Committee for Science and Technology (STC) on December 4 2002 to present evidence of its work and expenditure plans. Among the issues on the agenda are the Biobank and Stem Cell Bank projects (see Clinica No 1024, p 8). The Committee will consider comments on these and other areas of the MRC's work, by November 22. The meeting, which will be open to the public, is part of the ongoing programme of scrutiny of the UK's Research Councils, conducted under the STC's remit to examine the expenditure, policy and administration of the Office of Science and Technology and its associated public bodies.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.